B. Riley lowered the firm’s price target on Harrow to $26 from $30 and keeps a Buy rating on the shares following the Q4 report. The analyst says forward looking visibility into the company’s three core growth drivers “represented a surprise upside.” While the higher than projected spending ramp came as a slight surprise, this is reflective of the investment-heavy, market development phase Harrow finds itself in to realize its long-term growth potential, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow Health says CMS notification ‘very important development for IHEEZO’
- Harrow Health backs 2024 revenue guidance of at least $180M, consensus $184.91M
- Harrow Health reports Q4 core EPS (20c), consensus (4c)
- Harrow Health Inc Unveils Investor Presentation Update
- Options Volatility and Implied Earnings Moves Today, March 19, 2024